Concepedia

Amy Bartee

AB

3

Publications

226

Citations

3

H-Index

2021

Active since

Affiliations

Eli Lilly (United States)(Current)

Cleveland Clinic

The University of Texas Southwestern Medical Center

Center for Clinical Research (United States)

Amy Bartee is an author at Eli Lilly (United States) specializing in hyperglycemia, physiology, and diabetes.

Top concepts

Publications per year

2021–2025

3

Publications

3

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse et al. · American Heart Journal · 2023 · 194 citations · Full text

Predictive Low-Glucose Suspend Necessitates Less Carbohydrate Supplementation to Rescue Hypoglycemia: Need to Revisit Current Hypoglycemia Treatment Guidelines

Jordan E. Pinsker, Amy Bartee, Michelle L. Katz et al. · Diabetes Technology & Therapeutics · 2021 · 18 citations · Full text

, , +13

Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the <scp>SURMOUNT</scp> ‐ <scp>MMO</scp> trial

Carolyn S.P. Lam, Ángel Rodríguez, Ali Aminian et al. · Obesity · 2025 · 14 citations · Full text

Rows per page

1–3 of 3